ID: ALA2312736

Max Phase: Preclinical

Molecular Formula: C11H13BrN4O3

Molecular Weight: 329.15

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1ncc(Br)c2c1ncn2[C@@H]1C[C@H](O)[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C11H13BrN4O3/c12-4-2-14-11(13)7-8(4)16(3-15-7)5-1-6(17)10(19)9(5)18/h2-3,5-6,9-10,17-19H,1H2,(H2,13,14)/t5-,6+,9+,10-/m1/s1

Standard InChI Key:  NXSSDHAJPPWSRB-OFLNYADTSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 329.15

Molecular Weight (Monoisotopic): 328.0171

AlogP: -0.20

#Rotatable Bonds: 1

Polar Surface Area: 117.42

Molecular Species: NEUTRAL

HBA: 7

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.95

CX Basic pKa: 5.20

CX LogP: -1.14

CX LogD: -1.15

Aromatic Rings: 2

Heavy Atoms: 19

QED Weighted: 0.58

Np Likeness Score: 0.72

References

1. Liu C, Chen Q, Yang M, Schneller SW..  (2013)  C-3 halo and 3-methyl substituted 5'-nor-3-deazaaristeromycins: synthesis and antiviral properties.,  21  (1): [PMID:23176752] [10.1016/j.bmc.2012.09.051]

Source

Source(1):

• Scientific Literature